{"id":350370,"date":"2026-11-17T14:41:52","date_gmt":"2026-11-17T09:11:52","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=350370"},"modified":"2026-11-17T14:41:52","modified_gmt":"2026-11-17T09:11:52","slug":"electronics-manufacturing-company-oncology-drugs-maker-and-molecular-diagnostics-kits-maker-stocks-roadmap-downland-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/electronics-manufacturing-company-oncology-drugs-maker-and-molecular-diagnostics-kits-maker-stocks-roadmap-downland-list\/","title":{"rendered":"3 Electronics Manufacturing Company, Oncology Drugs Maker and Molecular Diagnostics Kits Maker Stocks With a Strong Future Roadmap: Dixon Technologies, Natco Pharma and Molbio Diagnostics"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Dixon Technologies, Natco Pharma and Molbio Diagnostics: ROE of 14.2% to 30.8% and FY22 to FY26 revenue CAGR of 16.8% to 46.7%. Prices as of 16 Nov 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three <strong>electronics, cancer drug and test kit stocks<\/strong> to watch are <strong>Dixon Technologies<\/strong>, <strong>Natco Pharma<\/strong> and <strong>Molbio Diagnostics<\/strong>. Their <strong>return on equity<\/strong> ranges from <strong>14.2% to 30.8%<\/strong>, and their <strong>revenue compound annual growth<\/strong> from FY22 to FY26 ranges from 16.8% to 46.7%. Dixon Technologies leads on both return on equity at 30.8% and revenue growth at 46.7% a year. Prices are based on the 16 November 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Electronics, cancer drug and test kit stocks give investors a way to track businesses that sit close to everyday demand in India. Dixon Technologies, Natco Pharma and Molbio Diagnostics cover an electronics manufacturing company, an oncology drugs maker and a molecular diagnostics kits maker.<\/p>\n<p>This list covers three electronics, cancer drug and test kit stocks with complete current figures: Dixon Technologies, Natco Pharma and Molbio Diagnostics. Every figure comes from the latest reported financials and the 16 November 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=electronics-manufacturing-company-oncology-drugs-maker-and-molecular-diagnostics-kits-maker-stocks-roadmap-downland-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/electronics-manufacturing-company-oncology-drugs-maker-and-molecular-diagnostics-kits-maker-stocks-roadmap-downland-list\/#What_Are_Electronics_Cancer_Drug_and_Test_Kit_Stocks\" title=\"What Are Electronics, Cancer Drug and Test Kit Stocks?\">What Are Electronics, Cancer Drug and Test Kit Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/electronics-manufacturing-company-oncology-drugs-maker-and-molecular-diagnostics-kits-maker-stocks-roadmap-downland-list\/#Electronics_Cancer_Drug_and_Test_Kit_Stocks_at_a_Glance\" title=\"Electronics, Cancer Drug and Test Kit Stocks at a Glance\">Electronics, Cancer Drug and Test Kit Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/electronics-manufacturing-company-oncology-drugs-maker-and-molecular-diagnostics-kits-maker-stocks-roadmap-downland-list\/#Why_Do_Electronics_Cancer_Drug_and_Test_Kit_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Electronics, Cancer Drug and Test Kit Stocks Have a Strong Roadmap in India?\">Why Do Electronics, Cancer Drug and Test Kit Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/electronics-manufacturing-company-oncology-drugs-maker-and-molecular-diagnostics-kits-maker-stocks-roadmap-downland-list\/#Why_Dixon_Technologies_Features_Among_These_Electronics_Cancer_Drug_and_Test_Kit_Stocks\" title=\"Why Dixon Technologies Features Among These Electronics, Cancer Drug and Test Kit Stocks\">Why Dixon Technologies Features Among These Electronics, Cancer Drug and Test Kit Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/electronics-manufacturing-company-oncology-drugs-maker-and-molecular-diagnostics-kits-maker-stocks-roadmap-downland-list\/#Why_Natco_Pharma_Features_Among_These_Electronics_Cancer_Drug_and_Test_Kit_Stocks\" title=\"Why Natco Pharma Features Among These Electronics, Cancer Drug and Test Kit Stocks\">Why Natco Pharma Features Among These Electronics, Cancer Drug and Test Kit Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/electronics-manufacturing-company-oncology-drugs-maker-and-molecular-diagnostics-kits-maker-stocks-roadmap-downland-list\/#Why_Molbio_Diagnostics_Features_Among_These_Electronics_Cancer_Drug_and_Test_Kit_Stocks\" title=\"Why Molbio Diagnostics Features Among These Electronics, Cancer Drug and Test Kit Stocks\">Why Molbio Diagnostics Features Among These Electronics, Cancer Drug and Test Kit Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/electronics-manufacturing-company-oncology-drugs-maker-and-molecular-diagnostics-kits-maker-stocks-roadmap-downland-list\/#Dixon_Technologies_vs_Natco_Pharma_vs_Molbio_Diagnostics_on_Key_Financials\" title=\"Dixon Technologies vs Natco Pharma vs Molbio Diagnostics on Key Financials\">Dixon Technologies vs Natco Pharma vs Molbio Diagnostics on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/electronics-manufacturing-company-oncology-drugs-maker-and-molecular-diagnostics-kits-maker-stocks-roadmap-downland-list\/#Key_Risks_to_Check_Before_Investing_in_Electronics_Cancer_Drug_and_Test_Kit_Stocks\" title=\"Key Risks to Check Before Investing in Electronics, Cancer Drug and Test Kit Stocks\">Key Risks to Check Before Investing in Electronics, Cancer Drug and Test Kit Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/electronics-manufacturing-company-oncology-drugs-maker-and-molecular-diagnostics-kits-maker-stocks-roadmap-downland-list\/#Final_Thoughts_on_Electronics_Cancer_Drug_and_Test_Kit_Stocks\" title=\"Final Thoughts on Electronics, Cancer Drug and Test Kit Stocks\">Final Thoughts on Electronics, Cancer Drug and Test Kit Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/electronics-manufacturing-company-oncology-drugs-maker-and-molecular-diagnostics-kits-maker-stocks-roadmap-downland-list\/#What_are_electronics_cancer_drug_and_test_kit_stocks\" title=\"What are electronics, cancer drug and test kit stocks?\">What are electronics, cancer drug and test kit stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/electronics-manufacturing-company-oncology-drugs-maker-and-molecular-diagnostics-kits-maker-stocks-roadmap-downland-list\/#Which_electronics_cancer_drug_and_test_kit_stocks_are_covered_in_this_list\" title=\"Which electronics, cancer drug and test kit stocks are covered in this list?\">Which electronics, cancer drug and test kit stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/electronics-manufacturing-company-oncology-drugs-maker-and-molecular-diagnostics-kits-maker-stocks-roadmap-downland-list\/#Why_do_electronics_cancer_drug_and_test_kit_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do electronics, cancer drug and test kit stocks have a strong future roadmap in India?\">Why do electronics, cancer drug and test kit stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/electronics-manufacturing-company-oncology-drugs-maker-and-molecular-diagnostics-kits-maker-stocks-roadmap-downland-list\/#How_has_Dixon_Technologies_performed_financially\" title=\"How has Dixon Technologies performed financially?\">How has Dixon Technologies performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/electronics-manufacturing-company-oncology-drugs-maker-and-molecular-diagnostics-kits-maker-stocks-roadmap-downland-list\/#How_has_Natco_Pharma_performed_financially\" title=\"How has Natco Pharma performed financially?\">How has Natco Pharma performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/electronics-manufacturing-company-oncology-drugs-maker-and-molecular-diagnostics-kits-maker-stocks-roadmap-downland-list\/#How_has_Molbio_Diagnostics_performed_financially\" title=\"How has Molbio Diagnostics performed financially?\">How has Molbio Diagnostics performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/electronics-manufacturing-company-oncology-drugs-maker-and-molecular-diagnostics-kits-maker-stocks-roadmap-downland-list\/#What_risks_should_investors_check_before_buying_electronics_cancer_drug_and_test_kit_stocks\" title=\"What risks should investors check before buying electronics, cancer drug and test kit stocks?\">What risks should investors check before buying electronics, cancer drug and test kit stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/electronics-manufacturing-company-oncology-drugs-maker-and-molecular-diagnostics-kits-maker-stocks-roadmap-downland-list\/#Is_this_list_of_electronics_cancer_drug_and_test_kit_stocks_investment_advice\" title=\"Is this list of electronics, cancer drug and test kit stocks investment advice?\">Is this list of electronics, cancer drug and test kit stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Electronics_Cancer_Drug_and_Test_Kit_Stocks\"><\/span><strong>What Are Electronics, Cancer Drug and Test Kit Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Electronics, cancer drug and test kit stocks<\/strong> are listed companies that make phones, televisions and appliances for global and Indian brands, make cancer and other specialty medicines, and make molecular diagnostic kits and tests. Their earnings depend on device production, specialty medicine demand and test kit demand.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Electronics_Cancer_Drug_and_Test_Kit_Stocks_at_a_Glance\"><\/span><strong>Electronics, Cancer Drug and Test Kit Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/dixon\/dixon-technologies-(india)-ltd-share-price-today\">Dixon Technologies<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12,990<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">70,805<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">34.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">43.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">30.8<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.21<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/natcopharm\/natco-pharma-ltd-share-price-today\">Natco Pharma<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">828.65<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15,708<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.08<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/molbio\/molbio-diagnostics-ltd-share-price-today\">Molbio Diagnostics<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,486.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16,605<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">101.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">59.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.38<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Dixon Technologies and Natco Pharma trade at a <strong>P\/E<\/strong> below the industry P\/E, while Molbio Diagnostics trades above it, which reflects the growth the market already expects. Readers comparing electronics, cancer drug and test kit stocks should look at <strong>return on equity<\/strong> and debt together, since a high return earned with low debt is easier to sustain.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Electronics_Cancer_Drug_and_Test_Kit_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Electronics, Cancer Drug and Test Kit Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Electronics, cancer drug and test kit stocks have a strong roadmap in India because fast growth of local electronics production, rising use of specialty medicines and wider use of molecular testing keep widening the market for these companies.<\/p>\n<ul>\n<li><strong>Electronics manufacturing.<\/strong> Brands move production to India.<\/li>\n<li><strong>Oncology drugs.<\/strong> Patients need advanced specialty medicines.<\/li>\n<li><strong>Molecular tests.<\/strong> Clinics need accurate diagnostic kits.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Dixon_Technologies_Features_Among_These_Electronics_Cancer_Drug_and_Test_Kit_Stocks\"><\/span><strong>Why Dixon Technologies Features Among These Electronics, Cancer Drug and Test Kit Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the <strong>electronics, cancer drug and test kit stocks<\/strong> on this list, Dixon Technologies is an electronics manufacturing services company that makes televisions, mobile phones, home appliances, lighting products and security devices for leading brands.<\/p>\n<p>In the June 2026 quarter, revenue grew 25.2% year on year to Rs 16,076 crore. Revenue rose from Rs 10,701 crore in FY22 to Rs 49,586 crore in FY26, a compound annual growth rate of 46.7%.<\/p>\n<p>Net profit grew from Rs 190 crore in FY22 to Rs 1,644 crore in FY26, which works out to a compound annual growth rate of 71.4%. The company has a return on equity of 30.8%, a debt to equity ratio of 0.21 and a <strong>market capitalisation<\/strong> of Rs 70,805 crore. The stock trades at a <strong>P\/E<\/strong> of 34.0, below the industry P\/E of 43.1.<\/p>\n<p><strong>Roadmap:<\/strong> The company is expanding into mobile phone and component manufacturing, supported by government incentives and growing local production. Partnerships with global brands widen its customer base.<\/p>\n<p><strong>What to watch:<\/strong> Follow mobile manufacturing volumes, component projects and new customer wins.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Natco_Pharma_Features_Among_These_Electronics_Cancer_Drug_and_Test_Kit_Stocks\"><\/span><strong>Why Natco Pharma Features Among These Electronics, Cancer Drug and Test Kit Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the phone maker, oncology generics and PCR kit shares on this list, Natco Pharma is a Hyderabad-based pharmaceutical company focused on complex generics, oncology, and active ingredients, with a significant presence in the United States and other regulated markets.<\/p>\n<p>The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P\/E of 13.7, below the industry P\/E of 36.0.<\/p>\n<p>Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%.<\/p>\n<p><strong>Roadmap:<\/strong> The company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.<\/p>\n<p><strong>What to watch:<\/strong> Check the timing of key product launches in the US and the contribution from new drug approvals.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Molbio_Diagnostics_Features_Among_These_Electronics_Cancer_Drug_and_Test_Kit_Stocks\"><\/span><strong>Why Molbio Diagnostics Features Among These Electronics, Cancer Drug and Test Kit Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Molbio Diagnostics, based in Goa, develops the Truenat platform, a portable molecular diagnostics system that delivers lab-grade PCR results at the point of care, with strong use in tuberculosis testing.<\/p>\n<p>Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%.<\/p>\n<p>The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P\/E of 101.2, above the industry P\/E of 59.6.<\/p>\n<p><strong>Roadmap:<\/strong> Its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.<\/p>\n<p><strong>What to watch:<\/strong> Order timing from public health programmes can be lumpy, so look at annual rather than single-quarter trends.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dixon_Technologies_vs_Natco_Pharma_vs_Molbio_Diagnostics_on_Key_Financials\"><\/span><strong>Dixon Technologies vs Natco Pharma vs Molbio Diagnostics on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three electronics, cancer drug and test kit stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Dixon Technologies<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">10,701<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">49,586<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">46.7%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,644<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3.3%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Natco Pharma<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,044<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,376<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">21.0%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,372<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">31.4%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Molbio Diagnostics<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">782<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,455<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.8%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">164<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.3%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Dixon Technologies posts the highest return on equity in this group at 30.8%. Dixon Technologies combines the largest FY26 revenue at Rs 49,586 crore with the fastest revenue growth, a 46.7% compound annual rate. A useful habit with electronics, cancer drug and test kit stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Electronics_Cancer_Drug_and_Test_Kit_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Electronics, Cancer Drug and Test Kit Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these <strong>electronics, cancer drug and test kit stocks<\/strong>, the main points are:<\/p>\n<ul>\n<li><strong>Demand cycles.<\/strong> Sales can vary with seasons and rates.<\/li>\n<li><strong>Regulatory approvals.<\/strong> Plant inspections and approvals can affect supplies.<\/li>\n<li><strong>Client spending.<\/strong> Technology budgets can vary with global conditions.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter electronics, cancer drug and test kit stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Electronics_Cancer_Drug_and_Test_Kit_Stocks\"><\/span><strong>Final Thoughts on Electronics, Cancer Drug and Test Kit Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Electronics, cancer drug and test kit stocks work best when investors track growth, valuation and return on equity side by side. Dixon Technologies, Natco Pharma and Molbio Diagnostics each have a clear plan to grow. Based on the 16 November 2026 close, Dixon Technologies trades at Rs 12,990, Natco Pharma at Rs 828.65 and Molbio Diagnostics at Rs 1,486.4.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track electronics, cancer drug and test kit stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_electronics_cancer_drug_and_test_kit_stocks\"><\/span><strong>What are electronics, cancer drug and test kit stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> <strong>Electronics, cancer drug and test kit stocks<\/strong> are listed companies that make phones, televisions and appliances for global and Indian brands, make cancer and other specialty medicines, and make molecular diagnostic kits and tests. Their earnings depend on device production, specialty medicine demand and test kit demand. This list looks at three of them, Dixon Technologies, Natco Pharma and Molbio Diagnostics, using reported FY22 to FY26 financials and the 16 November 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_electronics_cancer_drug_and_test_kit_stocks_are_covered_in_this_list\"><\/span><strong>Which electronics, cancer drug and test kit stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Dixon Technologies, Natco Pharma and Molbio Diagnostics. Based on the 16 November 2026 close, Dixon Technologies traded at Rs 12,990, Natco Pharma at Rs 828.65 and Molbio Diagnostics at Rs 1,486.4. Their return on equity ranges from <strong>14.2% to 30.8%<\/strong>, and their <strong>revenue compound annual growth<\/strong> from FY22 to FY26 ranges from 16.8% to 46.7%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_electronics_cancer_drug_and_test_kit_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do electronics, cancer drug and test kit stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Electronics, cancer drug and test kit stocks have a strong roadmap in India because fast growth of local electronics production, rising use of specialty medicines and wider use of molecular testing keep widening the market for these companies. The main drivers are as follows. Electronics manufacturing. Brands move production to India. Oncology drugs. Patients need advanced specialty medicines. Molecular tests. Clinics need accurate diagnostic kits. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Dixon_Technologies_performed_financially\"><\/span><strong>How has Dixon Technologies performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 10,701 crore in FY22 to Rs 49,586 crore in FY26, a compound annual growth rate of 46.7%. Net profit grew from Rs 190 crore in FY22 to Rs 1,644 crore in FY26, which works out to a compound annual growth rate of 71.4%. In the June 2026 quarter, revenue grew 25.2% year on year to Rs 16,076 crore. The company has a return on equity of 30.8%, a debt to equity ratio of 0.21 and a market capitalisation of Rs 70,805 crore. The stock trades at a P\/E of 34.0, below the industry P\/E of 43.1. Looking ahead, the company is expanding into mobile phone and component manufacturing, supported by government incentives and growing local production. Partnerships with global brands widen its customer base.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Natco_Pharma_performed_financially\"><\/span><strong>How has Natco Pharma performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%. The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P\/E of 13.7, below the industry P\/E of 36.0. Looking ahead, the company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Molbio_Diagnostics_performed_financially\"><\/span><strong>How has Molbio Diagnostics performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%. The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P\/E of 101.2, above the industry P\/E of 59.6. Looking ahead, its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_electronics_cancer_drug_and_test_kit_stocks\"><\/span><strong>What risks should investors check before buying electronics, cancer drug and test kit stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying electronics, cancer drug and test kit stocks. Demand cycles. Sales can vary with seasons and rates. Regulatory approvals. Plant inspections and approvals can affect supplies. Client spending. Technology budgets can vary with global conditions. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_electronics_cancer_drug_and_test_kit_stocks_investment_advice\"><\/span><strong>Is this list of electronics, cancer drug and test kit stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 16 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are electronics, cancer drug and test kit stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Electronics, cancer drug and test kit stocks are listed companies that make phones, televisions and appliances for global and Indian brands, make cancer and other specialty medicines, and make molecular diagnostic kits and tests. Their earnings depend on device production, specialty medicine demand and test kit demand. This list looks at three of them, Dixon Technologies, Natco Pharma and Molbio Diagnostics, using reported FY22 to FY26 financials and the 16 November 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which electronics, cancer drug and test kit stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Dixon Technologies, Natco Pharma and Molbio Diagnostics. Based on the 16 November 2026 close, Dixon Technologies traded at Rs 12,990, Natco Pharma at Rs 828.65 and Molbio Diagnostics at Rs 1,486.4. Their return on equity ranges from 14.2% to 30.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 16.8% to 46.7%.\"}},{\"@type\":\"Question\",\"name\":\"Why do electronics, cancer drug and test kit stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Electronics, cancer drug and test kit stocks have a strong roadmap in India because fast growth of local electronics production, rising use of specialty medicines and wider use of molecular testing keep widening the market for these companies. The main drivers are as follows. Electronics manufacturing. Brands move production to India. Oncology drugs. Patients need advanced specialty medicines. Molecular tests. Clinics need accurate diagnostic kits. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Dixon Technologies performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 10,701 crore in FY22 to Rs 49,586 crore in FY26, a compound annual growth rate of 46.7%. Net profit grew from Rs 190 crore in FY22 to Rs 1,644 crore in FY26, which works out to a compound annual growth rate of 71.4%. In the June 2026 quarter, revenue grew 25.2% year on year to Rs 16,076 crore. The company has a return on equity of 30.8%, a debt to equity ratio of 0.21 and a market capitalisation of Rs 70,805 crore. The stock trades at a P\/E of 34.0, below the industry P\/E of 43.1. Looking ahead, the company is expanding into mobile phone and component manufacturing, supported by government incentives and growing local production. Partnerships with global brands widen its customer base.\"}},{\"@type\":\"Question\",\"name\":\"How has Natco Pharma performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%. The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P\/E of 13.7, below the industry P\/E of 36.0. Looking ahead, the company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.\"}},{\"@type\":\"Question\",\"name\":\"How has Molbio Diagnostics performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%. The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P\/E of 101.2, above the industry P\/E of 59.6. Looking ahead, its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying electronics, cancer drug and test kit stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying electronics, cancer drug and test kit stocks. Demand cycles. Sales can vary with seasons and rates. Regulatory approvals. Plant inspections and approvals can affect supplies. Client spending. Technology budgets can vary with global conditions. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of electronics, cancer drug and test kit stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 16 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Electronics, Cancer Drug and Test Kit Stocks with a strong future roadmap: Dixon Technologies, Natco Pharma and Molbio Diagnostics. Compare price, valuation, return on equity and revenue growth as of 16 November 2026.<\/p>\n","protected":false},"author":28,"featured_media":350369,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[3803,24946,21098,764,16672,7909,14124,24948,24947,24949],"class_list":["post-350370","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-best-stocks","tag-cancer-drug-and-test-kit-stocks","tag-device-assembly","tag-dixon-technologies","tag-electronics","tag-molbio-diagnostics","tag-natco-pharma","tag-oncology-generics-and-pcr-kit-shares","tag-phone-maker","tag-specialty-medicines-and-diagnostics-kit-stocks"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["350369"],"rank_math_title":["Electronics, Cancer Drug and Molecular Test Stocks"],"rank_math_description":["Compare 3 electronics, cancer drug and test kit stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 16 Nov 2026."],"rank_math_focus_keyword":["electronics, cancer drug and test kit stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/3-electronics-manufacturing-company-oncology-drugs-maker-and-molecular.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350370","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=350370"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350370\/revisions"}],"predecessor-version":[{"id":350371,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350370\/revisions\/350371"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/350369"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=350370"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=350370"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=350370"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}